background the increase in high-risk injections and unsafe sexual behaviors has led to increased hiv infection prevalence among intravenous drug users (idus). the high costs of hiv/aids care and low financial resources necessitate an economic evaluation to make the best decision for the control of hiv/aids. objectives this study was conducted to determine the cost-effectiveness of methadone mai...

BACKGROUND Pediatric antiretroviral therapy (ART) has been shown to substantially reduce morbidity and mortality in HIV-infected infants and children. To accurately project program costs, analysts need accurate estimations of antiretroviral drug (ARV) costs for children. However, the costing of pediatric antiretroviral therapy is complicated by weight-based dosing recommendations which change a...

There are many problems associated with injection drug use, problems that affect both the users themselves as well as those close to them and the society in which they live. Whether through complications associated with drug use (multiple infections, mental health problems, etc) or through the consequences on those close to them and on society (family dysfunction, crime, etc), the costs of ille...

The effects of introducing a hospital formulary alone and with active intervention were compared prospectively with regard to drug costs and the quality of prescribing. Intervention comprised feedback on prescribing habits, peer comparison, and information on drugs. Aspects of prescribing that were not subjected to intervention did not alter. In the year in which intervention occurred generic p...

BACKGROUND Drugs are most typically defined as specialty because they are expensive; however, other criteria used to define a drug as specialty include biologic drugs, the need to inject or infuse the drug, the requirement for special handling, or drug availability only via a limited distribution network. Specialty drugs play an increasingly important role in the treatment of chronic conditions...

BACKGROUND Data regarding both drug-related and non-drug-related costs in patients with Parkinson's disease (PD) are scarce, mainly due to the difficulties in data acquisition in experimental designs. Likewise, the reported impact of drug costs on total direct costs varies across different studies. In addition, the influence of comorbidities on both treatment costs and health-related quality of...